Dr. Rimawi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1504 Taub Loop
Houston, TX 77030Phone+1 713-873-8890Fax+1 713-798-8884
Education & Training
- Baylor College of MedicinePost-Doctoral Fellowship, 2003 - 2005
- Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2004
- Baylor College of MedicineResidency, Internal Medicine, 1998 - 2001
- University of Jordan Faculty of MedicineClass of 1997
Certifications & Licensure
- TX State Medical License 2005 - 2026
- IN State Medical License 2004 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Neoadjuvant Herceptin in Patients With Breast Cancer Start of enrollment: 2001 Oct 01
- Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer Start of enrollment: 2003 Jan 01
- Neoadjuvant GW572016 to Treat Breast Cancer Start of enrollment: 2004 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsAdjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Corre...Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley
Journal of Clinical Oncology. 2024-11-01 - 2 citationsIRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer.Longyong Xu, Fanglue Peng, Qin Luo, Yao Ding, Fei Yuan
Cell. 2024-10-14 - Calibrating Observational Health Record Data Against a Randomized Trial.David Merola, Ulka Campbell, David Lenis, Sebastian Schneeweiss, Shirley Wang
JAMA Network Open. 2024-09-03
Journal Articles
- The Oral Selective Oestrogen Receptor Degrader (SERD) AZD9496 Is Comparable to Fulvestrant in Antagonising ER and Circumventing Endocrine ResistanceRinath Jeselsohn, Mothaffar F Rimawi, C Kent Osborne, Rachel Schiff, Nature
Press Mentions
- Greenwich LifeSciences Provides Year End UpdateDecember 29th, 2022
- NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast CancerJune 14th, 2022
- Long-Term Repercussions of Postponing Care Due to COVID-19March 8th, 2021
- Join now to see all
Professional Memberships
- Member
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: